These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 19020197)

  • 41. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Hampp C; Kauf TL; Saidi AS; Winterstein AG
    Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current respiratory syncytial virus prevention strategies in high-risk infants.
    Weisman LE
    Pediatr Int; 2002 Oct; 44(5):475-80. PubMed ID: 12225544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
    Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
    Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.
    Pollack P; Groothuis JR
    J Infect Chemother; 2002 Sep; 8(3):201-6. PubMed ID: 12373481
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab.
    Wu H; Pfarr DS; Losonsky GA; Kiener PA
    Curr Top Microbiol Immunol; 2008; 317():103-23. PubMed ID: 17990791
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit.
    Cox RA; Rao P; Brandon-Cox C
    J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nosocomial Respiratory Viral Infection in the Neonatal Intensive Care Unit.
    Vain NE
    Am J Perinatol; 2020 Sep; 37(S 02):S22-S25. PubMed ID: 32898879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Palivizumab in the prevention of respiratory syncytial virus disease.
    Krilov LR
    Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Respiratory syncytial virus: old challenges and new approaches.
    Chávez-Bueno S; Mejías A; Jafri HS; Ramilo O
    Pediatr Ann; 2005 Jan; 34(1):62-8. PubMed ID: 15693217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
    Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB
    Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Respiratory syncytial virus immune globulin: decisions and costs.
    Barton LL; Grant KL; Lemen RJ
    Pediatr Pulmonol; 2001 Jul; 32(1):20-8. PubMed ID: 11416872
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Palivizumab for respiratory syncytial virus prophylaxis.
    Sandritter T
    J Pediatr Health Care; 1999; 13(4):191-5; quiz 196-7. PubMed ID: 10690084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Respiratory syncytial virus prevention: past and present strategies.
    Greenough A; Thomas M
    Expert Opin Pharmacother; 2000 Sep; 1(6):1195-201. PubMed ID: 11249487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Effectiveness of passive immunisation against respiratory syncytium virus in a group of premature infants with birth weight below 1000 grams].
    Korbal P; Mikołajczak A; Szymański W
    Ginekol Pol; 2003 Oct; 74(10):1154-9. PubMed ID: 14669411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
    Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
    Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Palivizumab and the prevention of respiratory syncytial virus illness in pediatric patients with congenital heart disease.
    Feltes TF; Sondheimer HM
    Expert Opin Biol Ther; 2007 Sep; 7(9):1471-80. PubMed ID: 17727335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.
    Mejias A; Garcia-Maurino C; Rodriguez-Fernandez R; Peeples ME; Ramilo O
    Vaccine; 2017 Jan; 35(3):496-502. PubMed ID: 27692523
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab.
    Kassis C; Champlin RE; Hachem RY; Hosing C; Tarrand JJ; Perego CA; Neumann JL; Raad II; Chemaly RF
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1265-71. PubMed ID: 20304082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
    Rocca A; Biagi C; Scarpini S; Dondi A; Vandini S; Pierantoni L; Lanari M
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.